Last mentioned: Feb 21, 2026
Q4 2025 Earnings
Both companies report record performance and optimistic 2026 outlooks.
Payer Milestone
Talkspace surpasses 140 million covered lives through payer partnerships.
Talkspace Profitability
Talkspace achieves its first full quarter of adjusted EBITDA profitability.
Commercial Launch
Initial rollout of iDose TR begins in the U.S. market with targeted accounts.
iDose TR FDA Approval
Glaukos receives landmark approval for its travoprost intracameral implant.
Glaukos Corporation and Talkspace, Inc. reported strong Q4 2025 financial results, highlighting a successful transition toward high-margin, recurring revenue models. Glaukos saw significant gains from its iDose TR launch, while Talkspace solidified its position as a profitable, payer-led behavioral health leader.
This page surfaces every story mentioning Glaukos Corporation across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Glaukos Corporation was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |